Автореферат и диссертация по медицине (14.01.05) на тему:Функциональное состояние эндотелия и течение острого коронарного синдрома без подъема сегмента ST

Список сокращений и условных обозначений

ВВЕДЕНИЕ

Глава 1. ОБЗОР ЛИТЕРАТУРЫ

1.1 Эндотелий и его функции.

1.2 Эндотелиальная дисфункция и ИБС.

1.3 Факторы риска сердечнососудистых заболеваний и дисфункция эндотелия.

1.4 Роль оксидантного стресса в развитии эндотелиальной дисфункции.

1.5 Методы коррекции функции эндотелия.

1.6 Методы оценки функции эндотелия.

Глава 2. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ

2.1 Материалы исследования.

2.2 Методы исследования.

Глава 3. РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ

3.1 Функциональное состояние эндотелия при различных формах ИБС по результатам теста ЭЗВД ПА.

3.2 Биохимические маркеры эндотелиальной дисфункции при ОИМбпБТ и нестабильной стенокардии на 1-3 сутки от их развития.

3.3 Взаимосвязь уровня биохимических маркеров эндотелиальной дисфункции и результатов теста ЭЗВД ПА.

3.4 Динамика функции эндотелия по результатам теста ЭЗВД ПА и уровня биохимических маркеров эндотелиальной дисфункции за период наблюдения.

3.5 Взаимосвязь уровня биохимических маркеров эндотелиальной дисфункции и результатов теста ЭЗВД ПА на 7-14 сутки.

3.6 Уровень в/ч СРБ в плазме крови в различных группах больных и его взаимосвязь с биохимическими маркерами эндотелиальной дисфункции.

3.7 Влияние факторов риска на функцию эндотелия.

3.8 Влияние медикаментозной терапии на догоспитальном этапе на функцию эндотелия.

3.9 Влияние чрескожной транслюминальной коронарной ангиопластики со стентированием на функцию эндотелия.

3.10 Взаимосвязь между состоянием коронарных артерий и функцией эндотелия при OKC6nST.

3.11 Влияние функционального состояния эндотелия на течение OKC6nST.

3.12 Взаимосвязь уровня биохимических маркеров эндотелиальной дисфункции.

Глава 4. ОБСУЖДЕНИЕ РЕЗУЛЬТАТОВ 127 Практическикеие рекомендации 141 Выводы 142 Список литературы

СПИСОК СОКРАЩЕНИЙ И УСЛОВНЫХ ОБОЗНАЧЕНИЙ

АГ - артериальная гипертензия

АД - артериальное давление

АПФ - ангиотензин-превращающий фермент

АТ - ангиотензин в/ч СРБ- высокочувствительный С-реактивный белок

ГЛЖ - гипертрофия левого желудочка

ГМК — гладкомшечные клетки

ЗАП - затяжной ангинозный приступ

ИБС - ишемическая болезнь сердца

ИМ - инфаркт миокарда

ИТАП-1 - ингибитор тканевого активатора плазминогена 1 типа

ЛПВП - липопротеиды высокой плотности

ЛПНП - липопротеиды низкой плотности

ЛОНП - липопротеиды очень низкой плотности

НК - недостаточность кровообращения

ОИМ— острый инфаркт миокарда

ОКС - острый коронарный синдром

ОНМК - острое нарушение мозгового кровообращения

ПА - плечевая артерия

РААС - ренин-ангиотензин-альдостероновая система

ССЗ - сердечно-сосудистые заболевания

ТАП - тканевой активатор плазминогена

ТГ- триглицериды

УЗИ-- ультразвуковое исследование

ФВ - фракция выброса

ХМ - хиломикроны

ХС - холестерин

ХПН - хроническая почечная недостаточность

ХСН - хроническая сердечная недостаточность чсс- частота сердечных сокращений

ЧТКА - чрезкожная транслюминальная коронарная ангиопластика

ЧКВ -- чрезкожные коронарные вмешательства эд -- эндотелиальная дисфункция эзвд -- эндотелий зависимая вазодилятация эк -- эндотелиальные клетки

ЭКГ - электрокардиография эхо-кг - эхокардиография

1. Агеев Ф.Т. Роль эндотелиальной дисфункции в развитии и прогрессировании сердечно-сосудистых заболеваний // Сердечная недостаточность. 2003. - № 1. -С. 22-25

2. Аронов Д.М. Каскад терапевтических эффектов статинов // Кардиология. 2004.- № 10. С.85-94.

3. Аронов Д.М. Лечение и практика атеросклероза. М.: Триада-Х, 2000.

4. Аронов Д.М. Первичная и вторичная профилактика сердечно-сосудистых заболеваний интерполяция на Россию // Сердце - 2002.- № 3.- С. 109-112.

5. Аронов Д.М. Плеотропные эффекты статинов // РМЖ. 2001. - № 9. - С. 13-4.

6. Аронов Д.М. Профилактика атеросклероза у лиц с факторами риска и у больных ишемической болезнью сердца // Рус. мед. журн. 2000. - Т. 8. - № 7. -С. 351-364.

7. Аронов Д.М., Ахмеджанов Н.М., Гутковская Л.А. и др. Эффективность мероприятий по борьбе с факторами риска у больных ИБС, проводимых врачами первичного звена (по результатам опросов) // Рос. Кардиол. журн. -2006.-№3.-С. 34-40.

8. Барбараш О.Л., Кашталап В.В., Каретникова В.Н. и др. Клиническая значимость показателей эндотелиальной дисфункции, оксидативного стресса и гемостаза у больных инфарктом миокарда // Патол. кровообращ. и кардиохир. 2007. - № 2.- С. 28-33.

9. Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. М., 2001.

10. Ю.Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Эндотелиальная дисфункция при сердечной недостаточности: возможности терапии ингибиторами ангиотензинпревращающего фермента // Кардиология. 2001. - Т. 41. - № 5. - С. 100-104.

11. П.Бубнова М.Г. Как снизить уровень холестерина? Первые шаги к цели // Справ, поликлинич. врача. 2007. - Т. 5. - № 5.

12. Бубнова М.Г. Профилактика атеросклероза: новые тенденции в гиполипидемической терапии //Качество жизни. -2007. № 3. -С. 33-39.

13. Бубнова М.Г., Перова Н.В., Олферьев А.М., Красницкий В .Б., Лобикова C.B. Варианты чувствительности больных коронарной болезнью сердца к гиполипидемическому действию симвастатина // Кардиоваск. тер. и проф. -2002.-Т. 1. -№3.-С. 52-62.

14. Бувальцев В. И. Дисфункция эндотелия как новая концепция профилактики и лечения сердечно-сосудистых заболеваний // Международн. мед. журн. -2001. -№3.-С. 202-209.

15. Васюк Ю.А., Школьник Е.Л. Старые принципы новые горизонты в лечении ишемической болезни сердца // Кардиоваск. тер. и проф. - 2007. - Т. 6. - № 1. - С. 92-98.

16. Гогин Е.Е., Бубнова М.Г., Ткачева О.Н., Верткин А.Л. Как предотвратить трагическое развитие событий у кардиологического больного? // Леч. врач. — 2010. №6.

17. Голухова Е.З., Бокерия Л.А. Диагностика, прогнозирование и профилактика внезапной сердечной смерти у больных кардиологического профиля // Вестн. РОНЦ им. НН.Блохина РАМН. 2003. - № 11. - С. 56.

18. Гомазков O.A. Система эндотелиновых пептидов: механизмы кардио-васкулярных патологий // Вопр. мед. хим. —1999. № 4.

19. Гомазков O.A. Эндотелий "эндокринное дерево" // Биохимия. -1988. -Т. 63. -№2.-С. 12-20.

20. Долгов В.В., Шевенко О.П. Лабораторная диагностика нарушение обмена бежов. Учебное пособие. М., 2002. 67 с.

21. Кухарчук В.В., Бубнова М.Г., Кательницкая Л.И., и др. Эффективность и безопасность симвастатина у пациентов с гиперхолестеринемией. (результаты многоцентрового клинического исследования) // Кардиология. 2003. - № 5. -С. 42-47.

22. Мартынов А.И., Гороховская Г.Н. и др. Перспективы медикаментозного лечения эндотелиальной дисфункции // Фарматека. 2005. № 9. - С. 31-4.

23. Мкртумян А.М., Давыдов А.Л., Стрюк, Р.И., Полукаров M.JI. Роль дисфункции эндотелия в развитии гемодинамических нарушений и поздних сосудистых осложнений у больных сахарным диабетом 2-го типа//Рос. мед. вести. 2008Т. 13.-С. 36-48.

24. Мкртумян А.М., Полукаров М., Стрюк Р.И., Давыдов А.Л. Диабетическая макроангиопатия. Возможность доклинической диагностики // Болезни сердца и сосудов.-2008.-№2.

25. Небиеридзе Д.В., Оганов Р.Г. Дисфункция эндотелия как фактор риска атеросклероза, клиническое значение ее коррекции // Кардиоваск. тер. и проф. -2003.-Т. 2.-№3.-С. 86-89.

26. Омельяненко М.Г., Суховей H.A., Назаров С.Б., Плеханов В.Г. Клиническое значение эндотелиальной дисфункции при остром коронарном синдроме без подъема сегмента ST у лиц в возрасте до 55 лет // Рос. кардиол. журн. 2003. -Т. 42.-№4.-С. 36-40.

27. Остроумова О.Д., Дубинская Р.Э. Дисфункция эндотелия при сердечнососудистых заболеваниях // Кардиология. 2005. № 2. - С. 59-62.

28. Остроумова О.Д., Дубинская Р.Э. Старение и дисфункция эндотелия // Кардиоваск. тер. и проф. 2004. - № 4. - С. 83-89.

29. Сергиенко В.Б., Саютина Е.В., Самойленко JT.E. и др. Роль дисфункции эндотелия в развитии ишемии миокарда у больных ишемической болезнью сердца с неизмененными и малоизмененными коронарными артериями // Кардиология. 1999. - Т. 39. - № 1. — С. 25-30.

30. Стрюк Р.И. Комбинированная низкодозовая терапия артериальной гипертонии //Системн. гипертенз. -2009. №2.

31. Стрюк Р.И., Бухонкина Ю.М., Смирнова В.А., Чижова Г.В. Функция эндотелия и маточно-плодово-плацентарный кровоток у беременных с артериальной гипертонией // Кардиология. 2010. - № 4. - С. 18-22.

32. Стрюк Р.И., Длусская И.Г. Новый метод прогнозирования и оценки эффективности (З-адреноблокаторов у больных гипертонической болезнью // Кардиология. -1997. № 8. - С. 10-130.

33. Чижова Г.В., Стрюк Р.И., Бухонкина Ю.М., Смирнова В.А. Функция эндотелия и маточно-плодово-плацентарный кровоток у беременных с артериальной гипертонией // Кардиология. -2010. № 4. - С. 18-22.

34. Шпектор А.В., Васильева Е.Ю. Кардиология. Клинические лекции. М., 2008.

35. Ющук Е.Н., Васюк Ю.А., Хадзегова А.Б. и др. Эндотелиальная дисфункция при заболеваниях сердечно-сосудистой системы и методы ее коррекции // Клин, фармакол. и терапия. 2005. - Т. 14. - № 3. - С. 85-88.

36. Abassi Z.A., Tate J.E., Golomb Е. et al. Role of neutral endopeptidase in the metabolism of endothelin // Hypertension. -1992. Vol. 20. P. 89-95.

37. Adams M.R., Jessup W., Celermajer D.S. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin С // Am. Coll. Cardiol. 1997. - Vol. 29. - P. 491 -497.

38. AFC APS/TexC APS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS // JAMA. -1998. Vol. 279. - P. 1615-1622.

39. Al Suwaidi J.A., Hamasaki S., Higano S.T. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction // Circulation. 2000. - Vol. 101.-P. 948-954

40. Society of Thoracic Surgeons: endorsed by the American Association of

41. Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine // Circulation. 2007. - Vol. 116. - Vol. 7. - el 48-e304.

42. Anderson TJ., Uehata A., Gerhard M.D. et al. Close relation of endothelial function in the human coronary and peripheral circulation // J. Am. Coll. Cardiol. -1995. Vol. 26.-P. 1235-1241.

43. Andrews N.P., Prasad A., Quyyumi A.A. N-Acetylcysteine improves coronary and peripheral vascular function // J. Am. Coll. Cardiol. -2001. Vol. 37. -P. 117-123.

44. Anthony P. Davenport International Union of Pharmacology. Update on Endothelin Receptor Nomenclature // Pharmacol. Rev. 2002. - Vol. 54. P. 219-226.

45. Arnal J.F., Dinh-Xuan A.T., Pueyo M. et al. Endothelium-derived nitric oxide and vascular physiology and pathology // Cell. Mol. Life Sci. 1999. - Vol. 55. - N 8-9. - P. 1078-1087.

46. Arnold W.P., Mittal C.K., Katsuki S. et al. Nitric oxide activates guanylate cyclase and increases guanosine 3' :5' -cyclic monophosphate levels in various tissue preparations // Proc. Natl. Acad. Sei. USA. 1977. - Vol. 74. - P. 3203-3207.

47. Azumi H., Inoue N., Ohashi Y. et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase //Arterioscler. Thromb. Vase. Biol.-2002.-Vol. 22.-P. 1838-1844.

48. Bae S.W., Kim H.S., Cha Y.N. et al. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway // Biochem. Biophys. Res. Commun.-2003.- Vol. 306.-N4.-P. 981-987.

49. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase b, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex //Biol. Chem. 1996. - Vol. 271. -P. 16603-16608.

50. Balletshofer B.M., Rittig K., Enderle M.D. et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance // Circulation. 2000. Vol. 101. - P. 1780-1784.

51. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes // Cardiovasc. Res. 2004. - Vol. 63. - P. 582-592.

52. Bath P.M., Hassall D.O., Gladwin A.M. et al. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte Chemotaxis and adhesion to endothelium in vitro //Artenoscler. Thromb. 1991. - N 11. P. 254-260.

53. Battistelli S., Billi M., Manasse G. et al. Behavior of Circulating Endothelin-1 in a Group of Patients with Acute Myocardial Infarction // Angiology. 1999. - Vol. 50. -N8.-P. 629-638.

54. Behrendt D., Ganz P. Endothelial function. From vascular biology to clinical applications // Am. J. Cardiol. 2002. - Vol. 90. - P. 40L-48L.

55. Bendetowicz A.V., Wise R.J., Gilbert G.E. Collagen-bound von Willebrand factor has reduced affinity for factor VHI // J. Biol. Chem. -1999. Vol. 274. - P. 12300-12307.

56. Bonetti P.O., Lerman L.O., Napoli C., Lerman A. Statin effects beyond lipid lowering are they clinically relevant? // Eur Heart J. - 2003. -168. - N - 2. - P. 367-373.

57. Bonnefoy A., Yamamoto H., Thys C. et al. Shielding the front-strand beta 3 of the von Willebrand factor Al domain inhibits its binding to platelet glycoprotein Ibalpha// Blood.-2003.-Vol. 101.-P. 1375-1383.

58. Boo Y.C., Hwang J., Sykes M. et al. Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein by a protein kinase A-dependent mechanism // Am. J. Physiol. Heart. Circ. Physiol. 2002. - Vol. 283. - N 5. - P. H1819-H1828.

59. Bonies M., Heins M., Fischer Y. et al. Endothelin and big endothelin in coronaiy heart disease and acute coronary syndromes // Z. Kardiol. 1996. - Vol. 85. - N10. - P. 761-767.

60. Bosma P.J, Kooistra T. Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells // J. Biol. Chem. 1991. Vol. 266. -N27.-P. 17845-17849.

61. Bouloumie A., Bauersachs J., Linz W. et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production // Hypertension. 1997. - Vol. 30. - P. 934-941.

62. Boveris A. Mitochondrial production of superoxide radical and hydrogen peroxide // Adv. Exp. Med. Biol. 1977. - Vol. 78. - P. 67-82.

63. Brigelius-Flohe R., Traber M.G. Vitamin E: function and metabolism // FASEB J. -1999.-Vol. 13.-N1.-P. 145-1155.

64. Brooks A.R., Lelkes P.I., Rubanyi G.M. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow // Physiol. Genomics. 2002. -N 9.-P. 27-41.

65. Brown B.G., Zhao X.Q., Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease // N. Engl. J. Med. 2001. -Vol. 345.-P. 1583-1592.

66. Brown N.J., Agirbasli M., Vaughan D.E. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans // Hypertension. -1999. Vol. 34. P. 285-290.

67. Brown N.J., Gainer J.V., Stein C.M., Vaughan D.E. Bradykinin stimulates tissue plasminogen activator release in human vasculature // Hypertension. -1999. Vol. 33. -P. 1431-1435.

68. Broze Jr GJ. Tissue factor pathway inhibitor//Thromb. Haemost. -1995. Vol, 74. P. 90-93.

69. Brush Jr J.E., Faxon D.P., Salmon S. et al. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients // J. Am. Coll. Cardiol. -1992. Vol. 19. - P. 809-815.

70. Bucala R., Tracey I, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes // Clin. Invest. -1991. Vol. 87. - P. 432-438.

71. Buckley D.I., Fu R, Freeman M. et al. C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force // Ann Intern. Med. 2009. - Vol. 151. - P. 483-495.

72. Buttery L.D., Springall D.R., Chester A.H. et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite // Lab. Invest. 1996. - Vol. 75. - P. 77-85.

73. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress // Circ. Res. 2000. - Vol. 87. - P. 840-844.

74. Calabro P., Willerson J.T., Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary arteiy smooth muscle cells // Circulation. -2003.-Vol. 108.-P. 1930-1932.

75. Camacho M., Vila L. Transcellular formation of thromboxane a(2) in mixed incubations of endothelial cells and aspirin-treated platelets strongly depends on the prostaglandin i-synthase activity //Thromb. Res. 2000. - Vol. 99.-P. 155-164.

76. Campbell W.B., Gebremedhin D., Pratt P.F. et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors // Circ. Res. -1996. Vol. 78. -P. 415-423.

77. Cannon R. Role of nitric oxide in cardiovascular disease: focus on endothelium // Clin. Chem. 1998. - Vol. 44. P. 1808-1819.

78. Caramori P.R., Lima V.C., Seidelin P.H. et al. Long-Term Endothelial Dysfunction After Coronaiy Arteiy Stenting // J. Am. Coll. Cardiol. 1999. - Vol. 34. - N 6. - P. 1675-1679.

79. Cardillo C., Campia U., Kilcoyne C.M. et al. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension // Circulation. 2002. - Vol. 105. - P. 452-456.

80. Cardillo C., Kilcoyne C.M., Cannon HI R.O. et al. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo // Hypertension. -2000. Vol. 35. -N 6. -P. 1237-1241.

81. Cardillo C., Kilcoyne C.M., Waclawiw M. et al. Role of endothelin in the increases vascular tone of patients with essential hypertension // Hypertension. -1999. Vol. 33.-N2. P. 753-758.

82. Carr A., Krei B. Does vitamin C act as a pro-oxidant under physiological conditions? // FASEBJ.-1999.-Vol. 13.-P. 1007-1024.

83. Casey D.P., Beck D.T., Braith RW. Systemic plasma levels of nitrite/nitrate (NOx) reflect brachial flow-mediated dilation responses in young men and women // Clin. Exper. Pharmacol. Physiol. 2007. - Vol. 34. - N 12. -P. 1291-1293.

84. Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adult at risk of atherosclerosis // Lancet. — 1992.-Vol. 340.-P. 1111-1115.

85. Celermajer D.S., Sorensen K., Ryalls M. et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents // J. Am. Coll. Cardiol. -1993. Vol. 22. - P. 854-858.

86. Celermajer D.S., Sorensen K.E., Georgakopoulos D. et al. Cigarette smoking is associated with doserelated and potentially reversible impairment of endothelium-dependent dilation in healthy young adults // Circulation. 1993. - Vol. 88. - P. 21492155.

87. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J. et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women //J. Am. Coll. Cardiol. 1994. - Vol. 24. - P. 471-476.

88. Cesarman G.M., Guevara C.A., Hajijar K.A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation // J. Biol. Chem. -1994. -Vol. 269.-P. 21198-21203.

89. Chan N.N., Colhoun H.M. Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population // J. Am. Coll. Cardiol.-2001. Vol. 38. -P. 1814-1820.

90. Chandler W.L., Jascur M.L., Henderson PJ. Measurement of Different Forms of Tissue Plasminogen Activator in Plasma // Clin. Chemistry. 2000. - Vol. 46. - N 1. -P. 38-46.

91. Chandler W.L., Trimble S.L., Loo S.C, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma // Blood. -1990. Vol. 76. - P. 930 -937.

92. Chang P., Aronson D.L. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities // Thromb Haemost. -1997. Vol. 78. - P. 930 -933

93. Chen Y.-C., Walia R.P., Su M. et al. Sp 1 mediates glucose activation of the plasminogen activator inhibitor-1 promoter in vascular smooth muscle cells //J. Biol. Chem. 1998. - Vol. 273. - P. 18268-18272.

94. Chien M.C., Wu C.J., Yip H.K. et al. Increased circulating endothelin-1 in rheumatic mitral stenosis: irrelevance to left atrial and pulmonary pressures // Chest. -2004.-Vol. 125.-N 2.-P. 390-396.

95. Chignard M., Bailoy V, Renesto P. Leucocyte elastase-mediated release of von Willebrand factor from cultured endothelial cells. Eur Respir J. 1993;6:791-796.

96. Chowienczyk P J., Cockcroft J.R., Ritter J.M. Differential inhibition by NG-monomethyl-L-arginine of vasodilator effects of acetylcholine and methacholine in human forearm vasculature//Br. J. Pharmacol.- 1993.-Vol. 110.-P. 736-738.

97. Clarkson P., Celermajer D.S., Donald A.E. et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoproteincholesterol levels // J. Am. Coll. Cardiol. 1996. - Vol. 28. - P. 573-579.

98. Clarkson P., Celermajer D.S., Powe A.J. et al. Endothelium dependent dilatation is impaired in young healthy subjects with a family histoiy of premature coronary disease // Circulation. 1997. - Vol. 96. - P. 3378-3383.

99. Collet J.P., Montalescot G., Vicaut E. et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality // Circulation. 2003. - Vol. 108. - P. 391-394.

100. Collins T., Read M.A., Neish A.S. et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappaB and cytokine-inducible enhancers // EASEB 1995. - Vol. 9. - N 10. - P. 899-909.

101. Colucci M., Paramo J.A., Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation // J. Clin. Invest. -1985. Vol. 75. - N 3. - P. 818-823.

102. Conde I.D., Kleiman N.S. Arterial thrombosis for the interventional-cardiologist: from adhesion molecules and coagulation factors to clinical therapeutics // Catheter. Cardiovasc. Interv. -2003. Vol. 60. - P. 236-246.

103. Cook S., Hugli O., Egli M. et al. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice // Swiss. Med. Wkly. -2003.-Vol. 133. -P. 360-363.

104. Cook S., Scherrer U. Insulin resistance, a new target for nitric oxide-delivery drugs // Fundam. Clin. Pharmacol. -.2002. Vol. 16. - P. 441-453.

105. Cooke J.P., Losordo D.W. Nitric oxide and angiogenesis // Circulation. 2002. -Vol. 105.-P. 2133-2135.

106. Corder R., Carrier M., Khan N. et al. Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells // J. Cardiovasc. Pharmacol. -1995. Vol. 26.-Suppl.3.-P. S56-S58.

107. Corti R., Fuster V., Badimon J.J. Pathogenetic Concepts of Acute Coronary Syndromes // J. Am. Coll. Cardiol. 2003. - Vol. 41. - P. 7S-14S.

108. Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries // Circulation. 1995. - Vol. 91. -P. 139144.

109. Cosentino F., Hishikawa K., Katusic Z.S. et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells // Circulation. 1997. Vol. 96. - N 1. - P. 25-28.

110. Crabos M., Coste P., Paccalin M. et al. Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats // J. Mol. Cell. Cardiol. 1997. - Vol. 29. - P. 55-65.

111. Creager M.A., Cooke J.P., Mendelsohn M.E. et al. Impaired vasodilatation of forearm resistance vessels in hypercholesterolemic humans // J. Clin. Invest. 1990. -Vol. 86.-P. 228-234.

112. Cybulsky M.I., Gimbrone M.A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis // Science. 1991. - Vol. 251. - P. 788-791.

113. Cybulsky M.I., Iiyama K., Li H. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis//J. Clin. Invest.-2001.-Vol. 107.-P. 1255-1262.

114. Danesh J., Wheeler J.G., Hirschfield G.M. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronaiy heart disease //N. Engl. J. Med. 2004. - Vol. 350. -N 14. - P. 1387-1397.

115. Dejana E., Corada M., Lampugnani M.G. Endothelial cell-to-cell junctions // Faseb. J. -1995. -N 9. P. 910-918.

116. Dejana E., Valiron O., Navarro P. et al. Intercellular junctions in the endothelium and the control of vascular permeability // Ann NY Acad. Sei. -1997. -Vol. 811.-P. 36-43.

117. DeNicola L.R., Kissoon N., Duckworth L.J. et al. Exhaled nitric oxide as an indicator of severity of asthmatic inflammation // Pediatr. Emerg. Care. 2000. - Vol. 16.-P. 290-295.

118. Devaraj S., Dasu M.R, Singh U. et al. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo // Atherosclerosis. 2009. Vol. 203. -N l.-P. 67-74.

119. Devaraj S., Xu Y., Jialal I. C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial // Cells. Circulation. -2003.-Vol. 107.-N3.-P. 398-404.

120. Ding H., McGuire J., Triggle C. The other endothelium-derived relaxating factor. A review of recent findings concerning the nature and the cellular actions of endothelium-derived hyperpolarizing factor (EDHF) // Br. Med. Res. 2000. N11.-P. 119-129.

121. Dong F., Zhang X., Wold L.E. et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human. // Br. J. Pharmacol. 2005. - Vol. 145. -P. 323-333.

122. Dong J.F., Moake J.L., Nolasco L. ADAMTS-13 rapidly cleaves newly secreted ultralarge vonWillebrand factor multimers on the endothelial surface under flowing conditions // Blood. 2002. - Vol. 100. - P. 4033-4039.

123. Dong Q., Wright J.R. Expression of C-reactive protein by alveolar macrophages //J. Immunol. -1996. Vol. 156. -P. 4815-4820.

124. Dong Z.M., Chapman S.M., Brown A.A. et al. The combined role of P- and E-selectins in atherosclerosis // J. Clin. Invest. 1998. - Vol. 102. - P. 145-152.

125. Drake T. A., Morrissey J.H., Edgington T.S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis // Am. Pathol. 1989. - Vol. 134.-P. 1087-1097.

126. Duerrschmid N., Wippich N., Goettsch W. et al. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells // Biochem. Biophys. Res. Commun. -2000. Vol. 269. -N 3. -P. 713-717.

127. Duffy S.J., Gokce N., Holbrook M. et al. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension // Am. J. Physiol. Heart. Circ. Physiol. 2001. - Vol. 280. - P. H528-H534.

128. Duplain H., Burcelin R., Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase // Circulation. -2001. -Vol. 104.-P. 342-345.

129. Dupuis J., Goresky C.A., Rose C.P. et al. Endothelin-1 myocardial clearance, production, and effect on capillary permeability in vivo // Am. J. Physiol. 1997. -Vol. 273. -N 3. -Pt. 2. -P. H1239-H1245.

130. Dusting G J., Macdonald P.S. Endogenous nitric oxide in cardiovascular disease and transplantation // Ann Med. 1995. - Vol. 27. - P. 395^106.

131. Dyah W. Anggrahini, Noriaki Emoto, Kazuhiko Nakayama et al. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointimar formation following blood flow cessation // Cardiovasc. Res. 2009. - Vol. 82. - N 1.-P. 143-151.

132. Eich RF., Li T., Lemon D.D. et al. Mechanism of NO-induced oxidation of myoglobin and hemoglobin // Biochemistry. 1996. - Vol. 35. - P. 6976-6983.

133. Emeis J J. Regulation of the acute release of tissue-type plasminogen activatorfrom the endothelium by coagulation activation products // Ann N Y Acad. Sei. 1992. Vol. 667. - P. 249-258.

134. Emeis J.J., van den Eijnden-Schrauwen Y., van den Hoogen C.M. et al. An endothelial storage granule for tissue-type plasminogen activator// J. Cell. Biol. -1997. Vol. 139. - P. 245-256.

135. Enderle M.D., Pfohl M., Kellermann N. et al. Endothelial function, variables of fibrinolysis and coagulation in smokers and healthy controls // Haemostasis. 2000. -Vol. 30.-P. 149-158.

136. Ericksori L.A., Ginsberg M.H., Loskutoff D J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets // J. Clin. Invest. 1984. - Vol. 74. - P. 1465-1472.

137. Esmon C.T. Coagulation and inflammation // Endotoxin. Res. 2003. Vol. 9. -P. 192-198.

138. Esmon C.T. Protein C, protein S and thrombomodulin. In: Robert W., Colman M., Hirsh J. et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins, 2001. P. 335-353.

139. Essig M., Nguyen G., Prie D. et al. 3-Hydroxy-3-methylglutaiyl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins // Circ. Res. 1998. - Vol. 83. - P. 683-690.

140. Essler M., Retzer M., Bauer M. et al. Mildly oxidized LDL induses contraction of human endothelial cells through activation of rho|rho kinase and inhibition of myosin light chain phosphatase // J. Biol. Cem. 1999. - Vol. 274. P. 30361-30364.

141. Farb A., Kolodgie F.D., Hwang J.Y. et al. Extracellular matrix changes in stented human coronary arteries // Circulation. 2004. - Vol. 110. - N 8. - P. 940-947.

142. Feng Q., Lu X., Jones D.L. et al. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice // Circulation. 2001. Vol. 104. - P. 700-704.

143. Fichtischerer S., Breuer S. Prognostic Value of Systemic Endothelial Dysfunction in Patients With Acute Coronary Syndromes // Circulation. 2004. -Vol. 110.-P. 1926-1932.

144. Fichtischerer S., Rosenberger G., Walter D.H. et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease //Circulation.-2000.-Vol. 102.-P. 1000-1006.

145. Fleming I, Busse R. Signal transduction of ENOS activation // Cardiovasc. Res. -1999. Vol. 43. - P. 532-541.

146. Fleming I., Busse R. Molecular mechanisms involved ,n the regulation of the endothelial nitric oxide-vnthase // Am. J. Physiol. Regul. Integr. Comp. Physiol. -2003. Vol. 284. - P. R1-R12.

147. Fleming I., Michaelis U.R., Bredenkotter D. et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries // Circ. Res. 2001. - Vol. 88. -P. 44-51.

148. Folsom A.R., Wu K.K., Rosamond W.D. et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study // Circulation. 1997. - Vol. 96. - P. 1102-1108.

149. Fox K.A., Robison A.K., Knabb R.M. et al. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator // Circulation. -1985. -Vol.72.-P. 1346-1354.

150. Francis R.B. Jr., Kawanishi D., Baruch T. et al. Impaired fibrinolysis in coronary arteiy disease // Am. Heart. J. 1988. - Vol. 115. - P. 776-80.

151. Frederickson D.S., Lee R.S. A system for phenotyping hyperlipidemia // Circulation. -1965. Vol. 31. - P. 321-327.

152. Frey R.S., Rahman A., Kefer J.C. et al. PKCzeta regulates TNF-alpha-mduced activation of NADPH oxidase in endothelial cells // Circ. Res. 2002. - Vol. 90. - P. 1012-1019.

153. Frossard M., Fuchs I., Leitner J.M. et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction // Circulation. -2004. Vol. 110. -P. 1392-1397.

154. Fuchs I., Frossard M., Spiel A. et al. Platelet function in patients with acute coronaiy syndrome (ACS) predicts recurrent ACS // J. Thromb. Haemost. 2006. - N 4.-P. 2547-2552.

155. Fukuroda T., Fujikawa T., Ozaki S. et al. Clearance of circulating endothelin-1 by ETB receptors in rats // Biochem. Biophys. Res. Commun. -1994. Vol. 199. - P. 1461-1465.

156. Furberg C.D., Psaty B.M., FitzGerald G.A. Parecoxib, valdecoxib, and cardiovascular risk // Circulation. 2005. - Vol. 111. - P. 249.

157. Furchgott R.F., Zawadzki I.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine // Nature. —1980. Vol. 288. -P. 373-376.

158. Futterman L.G., Lemberg L. High sensitivity C-reactive protein is the most effective prognostic measurement of acute coronaiy events // J. Clin. Care. 2002. -Vol. 11.-N 5.-P. 482-486.

159. Galbusera M., Zoja C., Donadelli R. et at. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium // Blood. 1997. - Vol. 90.-N4.-P. 1558-15564.

160. Galle J., Heinloth A., Wanner C., Heermeier K. Dual effect of oxidized LDL on cell cycle in human endothelial cells through oxidative stress // Kidney Int. Suppl. -2001.-Vol. 78.-P. S120-SI23.

161. Gao X.R., Adhikari C.M., Peng L.Y. et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome // J. Pharm. Phamiacol. 2009. - Vol. 61. - N 11. - P. 15051510.

162. Gebuhrer V., Murphy J.F., Bordet J.C. et al. Oxidized low-density lipoprotein induces the expression of P-selectin (GMP140/PADGEM/CD62) on human endothelial cells//Biochem. J. 1995. - Vol. 306. -Ptl.-P. 293-298.

163. Gelehrter T.D., Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells // J. Clin. Invest. -1986. Vol. 77.-P. 165-169.

164. Gemici G., Erdim R, Tokay S. et al. Interaction between C-reactive protein and endothelin-1 in coronary arteiy disease // Cardiology. 2007. - Vol. 107. - N 4. - P. 340-344.

165. Ginsburg D., Zeheb R., Yang A.Y. et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells // J. Clin. Invest. 1986. - Vol. 78. - N 6. - P. 1673-1680.

166. Gold M.E., Wood K.S., Ng Methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein // Med. Scienc. 1990. - Vol. 87. - P. 4430-4434.

167. Golino P., Piscione F., Benedict C.R. et al. Local Effect of Serotonin Released during Coronary Angioplasty // N. Engl. J. Med. 1994. - Vol. 330. - N 8. - P. 523528.

168. Goran Bjelakovic M.D., Dimitrinka Nikolova, Lise Lotte Gluud, Rosa G. Simonetti. Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention // JAMA. 2007. - Vol. 297. - P. 842-857.

169. Graham A., Hogg N., Kalyanaraman B. et al. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor // FEBS Lett.-1993.-Vol. 330.-P. 181-185.

170. Gray G., Webb D. The endothelin system and its potential as a therapeutic target in cardiovascular disease // Pharmacol. Ther. 1996. Vol. 72. - P. 109-148.

171. Grewe P.H., Deneke T., Machraoui A. et al. Acute and Chronic Tissue Response to Coronary Stent Implantation: Pathologic Findings in Human Specimen // J. Am. Coll. Cardiol. 2000. - Vol. 35. - P. 157-163.

172. Grey S.T., Csizmadia V., Hancock W.W. Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cell versus endothelial cells, hit// J. Hematol. -1998. Vol. 67. P. 53-62.

173. Griendling K.K., Minien C. A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells // Circ. Res. 1994. - Vol. 74. - P. 1141-1148.

174. Grubina R, Huang Z., Shiva S. et al. Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy-and oxyhemoglobin // J. Biol. Chem. -2007. Vol. 282.-P. 12916-12927.

175. Gryglewski RJ. Interactions between endothelial mediators // Pharmacol. Toxicol. -1995. Vol. 77. - P. 1-9.

176. Gryglewski RJ., Chlopicki S., Swies J. et al. Prostacyclin, nitric oxide, and atherosclerosis // Ann NY Acad. Sei. 1995. - Vol. 748. - P. 194-206.

177. Guzik T J., West N.E., Black E. et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors // Circ. Res. 2000. - Vol. 86. - P. E85-E90.

178. Haines A.P., Howarth D., North W.R et al. Haemostatic variables and the outcome of myocardial infarction // Thromb. Haemost. -1983. Vol. 50. - P. 800803.

179. Halcox J.P.J., Schenk W.H., Zalos G. et al. Prognostic value of coronary vascular endothelial function // Circulation. 2002. - Vol. 106. - P. 653-658.

180. Hambrecht R, Adams V., Erbs S. et al. Regular physical improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase // Circulation. 2003. Vol. 107. - N 25. - P. 31523158.

181. Hambrecht R, Wolf A., Gielen S. Effect of exercise on coronary endothelial function in patients with coronary artery disease // N. Engl. J. Med. 2000. - Vol. 342. p. 454-460.

182. Hamsten A., de Faire U., Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction // Lancet. -1987. N 2. - P. 3-9.

183. Hamsten A., Wiman B., de Faire U., Blomblck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction//N. Engl. J. Med. 1985. - Vol. 313. -P. 1557-1563.

184. Hanss M., Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine // J. Lab. Clin. Med. 1987. - Vol. 109. - P. 97104.

185. Harrison D.G. Endothelial function and oxidant stress // Clin. Cardiol. -1997. -Vol. 20.-Nil.-P. 11-17.

186. Hayashi S., Watanabe N., Nakazawa K. et al. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries //Circulation.-2000. -Vol. 102.-P. 1710-1717.

187. He P., Liu B., Curry F.E. Effect of nitric oxide synthase inhibitors on endothelial Ca2+.I and microvessel permeability // Am. J. Physiol. 1997. - Vol. 272. -P. H176-H185.

188. Heitzer T., Krohn K., Albers S., Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus // Diabetologia. 2000. - Vol. 43. - N 11. -P. 1435-1438.

189. Heitzer T., Schlinzig T., Krohn K. et al. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients withcoronary artery disease // Circulation. -2001. Vol. 104. -N 22. -P. 2673-2678.

190. Hekman C.M., Loskutoff D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by dénaturants // J. Biol. Chem. 1985. -Vol. 260.-P. 11581-11587.

191. Hemler M.E., Elices M. J., Parker C., Takada Y. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions // Immunol. Rev. —1990. Vol. 14. -P. 45-65.

192. Herrera E., Barbas C. Vitamin E: action, metabolism and perspectives // J. Physiol. Biochem. 2001. - Vol. 57. - P. 43-56.

193. Herrington D.M., Reboussin D.M., Brosnihan K.B. et al. Effects of estrogen replacement on the progression of coronaiy-arteiy atherosclerosis // N. Engl. J. Med. -2000. Vol. 343. - P. 522-529.

194. Hevel J.M., Marietta M.A. Nitric-oxide synthase assays // Methods Enzymol. -1994.-Vol. 233.-P. 250-258.

195. Higgins D.L., Vehar G.A. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin // Biochemistry. -1987. -Vol. 26.-P. 7786-7791.

196. Hoetzer G.L., Stauffer B.L., Irmiger H.M. et al. Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women // J. Physiol. 2003. - Vol. 551. - P. 721-728.

197. Hofinan F.M., Chen P., Jeyaseelan R. et al. Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells // Blood. 1998. - Vol. 92. - P. 3064-3072.

198. Hojo Y., Ikeda U., Katsuki T. et al. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty // Cathet. Cardiovasc. Interv. 2000. - Vol. 51. - N 1. - P. 42-49.

199. Holland J.A., Pritchard K.A., Pappolla M.A. et al. Bradykinin induces superoxide anion release from human endothelial cells // J. Cell. Physiol. 1990. -Vol. 143.-N2.-P. 1-25.

200. Hollestelle M J., Thinnes T., Crain K. et al. Tissue distribution of factor VIH gene expression in vivo: a closer look // Thromb. Haemost. 2001. - Vol. 86. - P. 855-861.

201. Honing M.L., Smits P., Morrison P.J., Rabelink TJ. Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization // Hypertension. 2000. - Vol. 35. - P. 1314—1318.

202. Horning B., Maier V., Drexler H. Physical training improves endothelial function in patients with chronic heart failure // Circulation. 1996. - Vol. 93. - P. 210-214.

203. Horowitz A., Menice C.B., Laporte R., Morgan K.G. Mechanisms of smooth muscle contraction//Physiol. Rev.-1996.-Vol. 76.-P. 967-1003.

204. Hosoda K., Nakao K., Hiroshi-Arai. et al. Cloning and expression of human endothelin-1 receptor cDNA // FEBS Lett. 1991. - Vol. 287. - P. 23-26.

205. Howard M.A., Firkin B.G. Ristocetin: a new tool in the investigation of platelet aggregation // Thromb. Diath. Haemorrh. 1971. - Vol. 26. - P. 362-369.

206. Howard P.G., Plumpton C., Davenport A.P. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue // J. Hypertens. 1992. - Vol. 10. - P. 1379-1386.

207. Hoylaerts M., Rijken D.C., Lijnen H.R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin // J. Biol. Chem. -1982. Vol. 257. - P. 2912-2919.

208. Hrafnkelsdottir T, Erlinge D, Jern S. Extracellular nucleotides ATP and UTP induce a marked acute release of tissue-type plasminogen activator in vivo in man //

209. Thromb. Haemost. 2001. - Vol. 85. - N 5. - P. 875-881.i 167j

210. Hrafhkelsdottir Т., Gudnason Т., Wall U. et al. Regulation of local availability of active tissue-type plasminogen activator in vivo in man // J. Thromb. Haemost. — 2004.-VoL2.-Nll.-P. 1960-1968.

211. Hrafhkelsdottir Т., Wall U., Jern C., Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension // Lancet. 1998. - Vol. 352. P. 1597-1598.

212. Hu P., Ischiropoulos H., Beckman J.S., Matalon S. Peroxynitrite inhibition of oxygen consumption and sodium transport in alveolar type П cells // Am. J. Physiol. -1994. Vol. 266. - L628-L634.

213. Huber D., Cramer E.M., Kaufinann J.E. et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo // Blood. 2002. - Vol. 99. - P. 3637-3645.

214. Huo Y., Hafezi-Moghadam A., Ley K. Role of Vascular Cell Adhesion Molecule-1 and Fibronectin Connecting Segment-1 in Monocyte Rolling and Adhesion on Early Atherosclerotic Lesions // Circ. Res. 2000. - Vol. 87. - P. 153159.

215. Huo Y., Schober A., Forlow S.B. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein // Engl. Nat Med. 2003. -N 9. - P. 61-67.

216. Husain S.S., Hasan A.A.K., Budzynski A.Z. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-crosslinked and cross-linked fibrin clots //Blood. 1989. - Vol. 74. -P. 999-1006.

217. Husmann M., Dorffler-Melly J., Kalka C. et al. Successful lower extremity angioplasty improves brachial artery flow-mediated dilation in patients with peripheral arterial disease // J. Vase. Surg. 2008. - Vol. 48. -N 5. - P. 1211-1216.

218. Igic R., Behnia R. Properties and distribution of angiotensin I converting enzyme // Curr. Pharrn. Des. 2003. - N 9. - P. 697-706.

219. Ignarro L.J., Byrns R.E., Buga G.M. et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical // Circ. Res. 1987. - Vol. 61. - P. 866-879.

220. Inoue A., Yanagisawa M., Takuwa Y. et al. The human preproendothelin-1 gene I I J. Biol. Chem. -1989. Vol. 264. - P. 14954-14959.

221. Inoue N., Venema R.C., Sayegh H.S. et al. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1 // Arterioscler. Thromb. Vase. Biol. 1995. - Vol. 15. - N 8. - P. 1255-1261.

222. Inoue S., Kawanishi S. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide // FHBS Lett. 1995. - Vol. 371. - P. 86-88.

223. Ishizuka T., Takamizawa-Matsumoto M., Suzuki K. et al. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells // Eur. J. Pharmacol. -1999. Vol. 369. - P. 237245.

224. Jabs W.J., Logering B.A., Gerke P. et al. The kidney as a second site of human C-reactive protein formation in vivo // Eur. J. Immunol. 2003. - Vol. 33. - P. 152161.

225. Jambrik Z., Venneri L., Varga A. et al. Peripheral vascular endothelial function testing for the diagnosis of coronary arteiy disease // Am. Heart. J. 2004. - Vol. 148. -N4.-P. 684-689.

226. Janero D.R., Ewing J.F. Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential // Free Radic. Biol. Med. 2000. -Vol.29.N12.-P. 1199-221.

227. Jansson J.H., Nilsson T.K., Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death // Br. Heart. J. -1991. -Vol. 66.-P. 351-355.

228. Jem C., Selin L., Jern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress // Thromb. Haemost. -1994. Vol. 72. -P. 285-291.

229. Jialal I, Devaraj S. Role of C-reactive protein in the assessment of cardiovascular risk. Am J Cardiol. 2003;91:200-202.

230. Jialal I., Stein D., Balis D. et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels // Circulation. -2001.-Vol. 103.-P. 1933-1935.

231. Jilma B., Dirnberger E., Eichler H.G. et al. Partial blockade of nitric oxide synthase blunts the exercise-induced increase of von Willebrand factor antigen and of factor Vin in man // Thromb. Haemost. -1997. Vol. 78. P. 1268-1271.

232. Jilma B., Pernerstorfer T., Dirnberger E. et al. Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen // J. Lab. Clin. Med.-1998.-Vol. 131.-P. 151-156.

233. Joannides R., Haefeli W.E., Linder L. et al. Nitric oxide, is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo // Circulation. -1995.-Vol. 91.-P. 1314-1319.

234. John S., Delles .C, Jacobi J. et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks // J. Am. Coll. Cardiol. 2001. - Vol. 37. -N 5. - P. 1351-1358.

235. Johnson R.C., Chapman S.M., Dong Z.M. et al. Absence of P-selectin delays fatty streak formation in mice // Clin. Invest. -1997 -. Vol. 99. P. 1037-1043.

236. Johnstone M.T., Creager S.J., Scales K.M. et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus // Circulation.-1993.- Vol. 88.-P. 2510-2516.

237. Jones G.T., van Rij A.M., Solomon C. et al. Endothelin-l is increased overlying atherosclerotic plaques in human arteries // Atherosclerosis. -1996. Vol. 124. -N 1. -P. 25-35.

238. Kallas A., Talpsep T. The von Willebrand factor collagen-binding activity assay: clinical application // Ann Hematol. 2001. - Vol. 80. - P. 466-471.

239. Kanauchi M., Tsujimoto N., Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease // Diabetes Care. 2001. - Vol. 24. -P. 1620-1623.

240. Kanner J., Harel S., Granit R. Nitric oxide as an antioxidant // Arch. Biochem. Biophys. 1991. - Vol. 289. -P. 130-136.

241. Kansui Y., Fujii K., Goto K. et al. Angiotensin II receptor antagonist improves age-related endothelial dysfunction // J. Hypertens. 2002. - Vol. 20. - P. 439-446.

242. Karatzis E.N, Ikonomidis I., Vamvakou G.D. The long-Term Prognostic Role of Flow-Mediated Dilation of the Brachial Artery After Acute Coronary Syndromes Without ST Elevation // Am. J. Cardiol. 2006. - Vol. 98. - P. 1424-1428.

243. Karim S., Habib A., Levy-Toledano S. et al. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane// Biol. Chem.- 1996.-Vol. 271.-P. 12042-12048.

244. Katsaros K.M., Speidl W.S., Kastl S.P. et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents // J. Thromb. Haemostas. -2008. Vol. 6. - N 3. - P. 508-513.

245. Kerner T., Ahlers O., Reschreiter H. et al. Adhesion molecules in different treatments of acute myocardial infarction // Critical Care. 2001. -N 5. -P. 145-150.

246. Khreiss T., Jozsef L., Potempa L.A., Filep J.G. Conformational Rearrangement in C-Reactive Protein Is Required for Proinflammatoiy Actions on Human Endothelial Cells // Circulation. 2004. - Vol. 109. - N 16. - P. 2016-2022.

247. Kilhovd B.K., Berg T.J., Birkeland K.I. et al. Serum levels of advanced glycatiçn end products are increased in patients with type 2 diabetes and coronaiy heart disease // Diabetes Care. 1999. - Vol. 22. - P. 1543-1548.

248. Kinlay S., Schwertz G.G., Olsson A.G. et al. Endogenous tissue plasminogen activator and risk of recurrent recurrent cardiac events after an acute coronary syndrome in the MIRACL study // Atherosclerosis. 2009. - Vol. 206. - N 2. - P. 551555.

249. Klein N.J., Shennan G.I., Heyderman R.S. et al. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils // Cell. Sci. 1992. -Vol. 102.-P. 821-832.

250. Kobayashi S., Inoue N., Ohashi Y. et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein // Arterioscler. Thromb. Vase. Biol. 2003. - Vol. 23. - P. 1398-1404.

251. Koedam J. A., Meijers J.C., Sixma J. J., Bouma B.N. Inactivation of human factor VHI by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor//J. Clin. Invest.- 1988.-Vol. 82.-P. 1236-1243.

252. Kohno M., Yasumari K., Murakawa K. et al. Plasma immunoreactive endothelin in essential hypertension // Am. Med. 1990. - Vol. 88. -P. 614-618.s 172i

253. Kojda G., Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure // Cardiovasc. Res. 1999. - Vol. 43. - N 3. - P. 562-571.

254. Koppenol W.H., Moreno J.J., Piyor W.A. et al. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide // Chem. Res. Toxicol. 1992. - N 5. - P. 834842.

255. Kruithof E.K. Plasminogen activator inhibitors. A review // Enzyme. 1988. -Vol. 40.-P. 113-121.

256. Kruithof E.K., Trab-Thang C, Ransijn A., Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma // Blood. -1984. Vol. 64.-P. 907-913.

257. Kruithof E.K., Vasalli J.D., Schleuning W.D. et al. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937 //J. Biol. Chem. 1986. - Vol. 261. -P. 11207-11213.

258. Kukreja R.C., Kontos H.A., Hess M.L., Ellis E.F. PGH synthase and lipoxygenase generate superoxide in the presence ofNADH or NADPH // Circ. Res. -1986.-Vol. 59.-P. 612-619.

259. Kunsch C., Medford RM. Oxidative stress as a regulator of gene expression in the vasculature // Circ. Res. 1999. - Vol. 85. - P. 753-766.

260. Kushwaha R.S. Female sex steroid hormones and lipoprotein metabolism // Curr. Opin. Lipidol. 1992. -N 3. - P. 167-172.

261. Laakso K. Hyperglycemia and cardiovascular disease in type 2 diabetes // Diabetes. -1999. Vol. 48. - P. 937-942.

262. Langenfeld M.R., Nakhla S., Death A.K. et al. Endothelin-1 plus oxidised low-density lipoprotein, but neither alone, increase human monocyte adhesion to endothelial cells //Clin. Sci. 2001. - Vol. 101. -N 6.-731-738.

263. Lauer T., Heiss C., Balzer J. et al. Age-dependent endothelial dysfunction is associated with failure to increase plasma nitrite in response to exercise // Basic. Res. Cardiol. 2008.- Vol. 103. -N 3. - P. 291-297.i. \

264. Laursen J.B., Somers M., Kurz S. et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin//Circulation.-2001.-Vol. 103.P. 12S2 1288.

265. Leahy K., Koki A., Masferrer J. Role of cyclooxygenase in angiogenesis // Curr. Med. Chem. 2000. - N 7. - P. 1163-1170.

266. Lerman A., Burnett J.C. Jr, Higano S.T. et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans // Circulation. -1998. Vol. 97. -P. 2123-2128.

267. Lerman A., Edwards B.S., Hallett J.W. et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis //N. Engl. J. Med. -1991. Vol. 325. -P. 997-1001.

268. Lennan A., Kubo S.H., Tschumperlin L.K., Burnett J.C. Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation // J. Am. Coll. Cardiol. -1992. Vol. 20. - P. 849-853.

269. Levin E.R. Mechanisms of disease: endothelins // N. Engl. J. Med. -1995. -Vol. 333.-P. 356-363.

270. Levine J.D., Harlan J.M., Harker L.A. et al. Thrombinmediated release of factor Vm antigen from human umbilical vein endothelial cells in culture // Blood. -1982. -Vol. 60.-P. 531-534.

271. Li H., Burkhardt C., Heinrich U.R et al. Histamine upregulates gene expression of endothelial nitric oxide synthase in human vascular endothelial cells // Circulation. -2003. Vol. 107. - N 18. - P.:2348-2354.

272. Li H., Cybulsky M.I., Gimbrone M.A. Jr., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium // Arterioscler. Thromb. 1993. - Vol. 13. - P. 197-204.

273. Liaw P.C., Neuenschwander P.F., Smirnov M.D. et al. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function // J. Biol. Chem. 2000. - Vol. 275. - P. 5447-5452.

274. Libby P. Inflammation in atherosclerosis // Nature. 2002. - Vol. 420. - P. 868-874.

275. Lieberman E.H., Gerhard M.D., Uehata A. et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women // Ann Intern. Med. -1994. Vol. 121. -P. 936-941.

276. Lin M.C., Almus- Jacobs F., Chen H.H. et al. Shear stress induction of the tissue factor gene // Clin. Invest 1997. - Vol. 99. - P. 737-744.

277. Lindahl T.L., Sigurdardottir O., Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1)//Thromb. Haemost.-1989.-Vol. 62. -N2.-P. 748-751.

278. Liu M., Wang F., Wang Y., Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation // Cardiovacs. Drugs. Ther. 2009. - Vol. 23. - N 5. - P. 369-376.

279. Lollar P., Hill-Eubanks D.C., Parker C.G. Association of the factor Vm light chain with von Willebrand factor//J. Biol. Chem.- 1988.-Vol. 263. -10451-10455.

280. Loscalzo J., Welch G. Nitric oxide and its role in the cardiovascular system // Prog. Cardiovasc. Dis. 1995. - Vol. 38. - P. 87-104.

281. Lounsbury K.M., Hu Q., Ziegelstein R.C. Calcium signaling and oxidant stress in the vasculature // Free Radic. Biol. Med. 2000. - Vol. 28. - P. 1362-1369.

282. Lowe G.D., Danesh J., Lewington S. et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis // Eur. Heart. J. -2004. Vol. 25. - P. 252-259.

283. Luc G., Arveiler D., Evans A. et al. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study // Atherosclerosis. 2003. - Vol. 170. -N 1. - P. 169-176.

284. Ludmer P.L., Selwyn A.P., Shook T.L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerosis coronary arteries //N. Engl. J. Med. -1986.-Vol. 315.-P. 1046-1051.

285. Lukacs N.W., Strieter R.M., Einer V. et al. Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions // Blood. 1995. - Vol. 86. - P. 2767-2773.

286. Lum H., Malik A.B. Mechanisms of increased endothelial permeability // Can. J. Physiol. Pharmacol. 1996. - Vol. 74. - P. 787-800.

287. MacGregor I.R., Booth N. A. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI-1) // Thromb. Haemost. 1988. - Vol. 59. - N 1. - P. 68-72.

288. Maclouf J., Folco G., Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease // Thromb. Haemost. -1998.-Vol. 79. -P. 691-705.

289. Mancini G.B J., Henry G.C., Macaya C. et al. Angiotensin-Converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study // Circulation. 1996. - Vol. 94. - P. 258265.

290. Mann K.G. Thrombosis: theoretical considerations // Am. J. Clin. Nutr. 1997. -Vol. 65.-P. 1657S-1664S.

291. Mannucci P.M. Platelet von Willebrand factor in inherited and acquired bleeding disorders // Proc. Natl. Acad. Sei. USA. 1995. - Vol. 92. - P. 2428-2432.

292. Mannucci P.M., Ruggeri Z.M., Pareti F.I., Capitanio A. l-Deamino-8-darginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases //Lancet. 1977. - Vol. 1. - P. 869-872.

293. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women // J. Cardiovasc. Pharmacol. -2000. Vol. 36. - P. 617-621.

294. Marcum J.A., McKenney J.B., Rosenberg R.D. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium // Clin. Invest. 1984. - Vol. 74. -P. 341-350.

295. Marcus A., Broekman M., Drosopoulos J. et al. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-l: implications for ischemic vascular diseases // J. Pharmacol. Exp. Ther. 2003. - Vol. 305. - N 1. - P. 916.

296. Marietta M. A. Nitric oxide synthase: aspects concerning structure and catalysis // Cell. 1994. - Vol. 78. - P. 927-930.

297. Mark A.L., Correia M., Morgan D.A. et al. Obesity-induced hypertension. New concepts from de emerging biology of obesity // Hypertension. -1999. Vol. 33. - R. E.-P. 537-541.

298. Martin T., Cardarelli P.M., Pany G.C. et al. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action ofNF-kappa b and AP-1 // Eur. Immunol. -1997. Vol. 27. - P. 1091-1097.

299. Matsubara T., Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines // J. Immunol. 1986. - Vol. 137. - P. 32953298.

300. McCrohon J.A., Adams M.R., McCredie R.J. et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women// Clin. Endocrinol. (Oxford). -1996. Vol. 45. -P. 435-441.

301. McGorisk G.M., Treasure C.B. Endothelial dysfunction in coronary arteiy disease // Curr. Opin. Cardiol. 1996. - Vol. 11. - P. 341-350.

302. Mclntyre T.M., Modur V., Prescott S.M. et al. Molecular mechanisms of early inflammation // Thromb. Haemost. -1997. Vol. 78. - P. 302-305.

303. Meade T.W., Cooper J.A., Stirling Y. et al. Factor VIII, ABO blood group and the incidence of ischaemic heart disease // Br. J. Haematol. 1994. - Vol. 88. - P. 601-607.

304. Meneshian A., Bulkley G.B. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction // Microcirculation. 2002. - N 9. - P. 161 -175.

305. Mian-Shin Tan, Yau-Jiunn Lee, Shyi-Jang Shin, Juei-Hsiung Tsai. Oxidized low-density lipoprotein stimulates endothelin-1 release and mRNA expression from rat mesangial // Cells. Translat. Res. 1997. - Vol. 129. -N 2. - P. 224-230.

306. Michel T., Feron O. Nitric oxide synthases: which, where, now, and why? // Clin. Invest. -1997. Vol. 100. - P. 2146-2152.

307. Michelson A.D., Benoit S.E., Furman M.I. et al. Effects of nitric oxide/EDRF on platelet surface glycoproteins // Am. J. Physiol. 1996. - Vol. 270. - P. HI 640-H1648.

308. Millette E., de C J., Lamontagne D. Altered coronary dilation in deoxycorticosterone acetate-salt hypertension // J. Hypertens. 2000. - Vol. 18. - P. 1783-1793.

309. Mohazzab K.M., Kaminski P.M., Wolin M.S. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium // Am. J. Physiol. -1994. Vol. 266. - P. H2568-H2572.

310. Molenaar P., O'Reilly G., Sharkey A. et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium//Circ/Res.- 1993.-Vol. 72.-P. 526-538.

311. Molet S., Kanako Furukawa, Maghazechi A. et al. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells // J. Allergy Clin. Immunol. 2000. - Vol. 105. - N 2. - P. 333-338.

312. Moncada S., Higgs E.A. Endogenous nitric oxide: physiology, pathology and clinical relevance // Eur. J. Clin. Invest. 1991. - Vol. 21. - P. 361-374.

313. Moncada S., Vane J.R. Prostacyclin and its clinical applications // Ann Clin. Res. -1984. Vol. 16. - P. 241-252.

314. Montalescot G., Collet J.P., Lison L. et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina // J. Am. Coll. Cardiol. -2000.-Vol. 36.-P. 110-114.

315. Morigi M., Angioletti S., Imberti B. et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in aNF-kB-dependent fashion//Clin. Invest.-1998. -Vol. 101.-P. 1905-1915.

316. Motoyama T., Kawano H., Kugiyama K. et al. Flow-mediated, endothelium-dependent dilatation of the brachial arteries is impaired in patients with coronary spastic angina // Am. Heart. J. -1997. Vol. 133. - P. 263-267.

317. Mukheijee S., Coaxum S.D., Maleque M. et al. Effects of oxidized low density lipoprotein on nitric oxide synthetase and protein kinase C activities in bovine endothelial cells // Cell. Mol. Biol. -2001,- Vol. 47. P. 1051-1058.

318. Mulder A.B., Hegge-Paping K.S., Magielse C.P. et al. Tumor necrosis factor alpha-induced endothelial tissue factor is located on the cell surface rather than in the subendothe-lial matrix // Blood. 1994. - Vol. 84. - P. 1559-1566.

319. Muller L., Valdenaire O., Barret A. et al. Expression of the endothelin-converting enzyme-1 isoforms in endothelial cells // Cardiovasc. Pharmacol. 2000. -Vol. 36.-P. S15-S18.

320. MuroharaT., Parkinson S.J., Waldman S.A., Lefer A.M. Inhibition ofhitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C //Arterioscler. Thromb. Vase. Biol. -1995. Vol. 15. -P. 2068-2075.

321. Nakashima Y., Raines E.W., Plump A.S. et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse // Arterioscler. Thromb. Vase. Biol. 1998. - Vol. 18. - P. 842-851.

322. Napoli C., de Nigris F., Palinski W. Multiple role of reactive oxygen species in the arterial wall // J. Cell. Biochem. 2001. - Vol. 82. - P. 674-682.

323. Narita M., Bu G., Herz J., Schwartz A.L. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo // J. Clin. Invest. 1995. - Vol. 96. -P. 1164-1168.

324. Nathan C., Xie Q. W. Regulation of biosynthesis of nitric oxide // J. Biol. Chem. -1994. Vol. 269. - P. 13725-13728.

325. Newby D.E., Witherow F.N., Wright R.A. et al. Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo // Heart. 2002. - Vol. 87. - P. 48-53.

326. Newby D.E., Wright R.A., Dawson P. et al. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man // Cardiovasc. Res. 1998. - Vol. 38. - P. 485^192.

327. Newby D.E., Wright R.A., Labinjoh C. et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction // Circulation. 1999.- Vol. 99. - P. 1411-1415.

328. Newby D.E., Wright R.A., Ludlam C.A. et al. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium // Thromb. Haemost. -1997.-Vol. 78.-P. 1242-1248.

329. Niccoli G., Lanza G.A., Shaw S., Romagnoli E. et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization // Eur. Heart J. Enzymol. 1994. - Vol. 233. - P. 250-258.

330. Nichols W.C., Cooney K.A., Ginsburg D., Ruggeri Z.M. von Willebrand disease. In: Loscalzo J., Schafer A.I. (eds). Thrombosis and Hemorrhage. Philadelphia: Lippincott, Williams & Wilkins, 2003. P. 539-559.

331. Nilsson L., Banfi C., Diczfalusy U. et al. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells // Arterioscler. Thromb. Vase. Biol. -1998. Vol. 18. -P. 1679-1685.

332. Nilsson L., Gafvels M., Musakka L. et al. VLDL activation of plasminogen activator inhibitor-1 (involvement of the VLDL receptor // J. Lipid. Res. -1999. Vol. 40.-P. 913-981.

333. Nitenberg A., Antony I., Foult J.M. Acetylcholine-induced coronary vasoconstriction in young, heavy smokers with normal coronary angiographic findings //Am. Med. -1993 Vol. 95. P. 71-77.

334. Nordenhem A., Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes // Scand. J. Clin. Lab. Invest.- 1998.-Vol. 58.-N6.-P. 475-483.

335. Nystrom T., Nygren A., Sjoholm A. Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction // Clin. Sci. 2005. - Vol. 108. - N 2. - P. 121-128.

336. O'Connor T.M., O'Connell J., O'Brien D.I. et al. The role of substance P in inflammatory disease // J. Cell. Physiol. 2004. - Vol. 201. - P. 67-180.

337. O'Driscoll G., Green D., Rankin J. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus // J. Clin. Invest. -1997. Vol. 100. - P. 678-684.

338. Okie S. Raising the safety bar the FDA's coxib meeting // N. Engl. J. Med. -2005.-Vol. 352. - P. 1283-1285.

339. Olken N.M., Marietta M.A. NG-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase // Biochemistry. -1993. Vol. 32. P. 9677-9685.

340. Osterlund B., Andersson B., Haggmark S. et al. Myocardial ischemia induces coronary t-PA release in the pig // Acta Anaesthesiol. Scand. 2002. - Vol. 46. - P. 271-278.

341. Pacher R., Stanek B., Hulsmann M. et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure //J. Am. Coll. Cardiol. -1996. Vol. 27. - P. 633-641.

342. Paez A., Mendez-Cruz A.R., Varela E. et al. HUVECs from newborns with a strong family history of myocardial infarction overexpress adhesion molecules and react abnormally to stimulating agents // Clin. Exp. Immunol. 2005. - Vol. 141. - P. 449-458.

343. Paimany B. Clinical application of high-sensitivity C-reactive protein. Cardiol. Rev. 2002.19 (2): 19-22.

344. Paleolog E.M., Crossman D.C., McVey J.H., Pearson J.D. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells // Blood. -1990. Vol. 75. P. 688-695.

345. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor // Nature. 1987. - Vol. 327.-P. 524-526.

346. Panasenko O.M., Sharov V.S., Briviba K., Sies H. Interaction ofperoxynitrite with carotenoids in human low density lipoproteins // Arch. Biochem. Biophys. -2000. Vol. 373. - P. 302-305.

347. Pannocchia A., Garis G., Giorgianni A. et al. Nitroprusside has no effect on t-PA and PAI production and release by endothelial cells in culture // Fibrinolysis. -1996.-Vol. 10.-P. 111-115.

348. Panza J. A., Quyyumi A. A., Brush J.E. Jr, Epstein S.E. Abnormal endothe-lium-dependent vascular relaxation in patients with essential hypertension //N. Engl. Med. — 1990.-Vol. 323.-P. 22-27.

349. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells // Circulation. 2000. - Vol. 102. - P. 2165-2168.

350. Pearson T. A., Mensah G.A., Alexander R. W. et al. Markers of inflammation and cardiovascular disease-application to clinical and public health practice // Circulation. 2003. - Vol. 107. - P. 499-511.

351. Perreault M., Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle // Nat. Med. 2001. -N 7. -P. 1138-1143.

352. Perticone F., Ceravolo R, Pujia A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients // Circulation. 2001. - Vol. 104/ - P. 191-196.

353. Pigazzi A., Heydrick S., Folli F. et al. Nitric oxide inhibits thrombin receptor-activating peptide-induced phos-phoinositide 3-kinase activity in human platelets // Biol. Chem. -1999. Vol. 274. - P. 14368-14375.

354. Pinsky D.J., Naka Y., Liao H. et al. Hypoxia-inducedexocytosis of endothelial cell Weibel-Palade bodies: a mechanism for rapid neutrophil recruitment after cardiac preservation // J. Clin. Invest. -1996. Vol. 97. - P. 493-500.

355. Plow E.F., Felez J., Miles L. A. Cellular regulation of fibrinolysis // Thromb. Haemost. -1991. Vol. 66. -P. 32-36.

356. Podrez T.K., Schmitt D., Hoff H.F., Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro // J. Clin. Invest.-1999.-Vol. 103.-P. 1547-1560.

357. Popp R., Fleming I., Busse R. Pulsatile stretch in coronary arteries elicits release of endothelium-derived hyperpolarizing factor: a modulator of arterial compliance // Circ. Res. -1998. Vol. 82. - P. 696-703.

358. Prasad A., Andrews N.P., Padder F.A. et al. Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability // J. Am. Coll. Cardiol. -1999. -Vol. 34.-P. 507-514.

359. Prasad A., Halcox J.P. J, Waclawiw M.A, Quyyumi A.A. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis // J. Am. Coll. Cardiol. -2001. Vol. 38. -P. 1089-1095.

360. Prasad A., Tupas-Habib T., Schenke W.H. et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis // Circulation. -2000.- Vol. 101. -P. 2349-2354.

361. Predel H.G., Meyer-Lehnert H., Bäcker A. et al. Plasma concentrations of endothelin in patients with abnormal vascular reactivity. Effects of ergometric exercise and acute saline loading //Life Sei. -1990. Vol. 47. -P. 1837-1843.

362. Pretorius M., Rosenbaum D.A., Lefebvre J. et al. Smoking impairs bradykinin-stimulated t-PA release // Hypertension. 2002. - Vol. 39. - P. 767-771.

363. Price J.F., Mowbray P.I., Lee A J. et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease andcoronary artery disease: Edinburgh Artery Study I I Eur. Heart. J. -1999. Vol. 20. -P. 344-353.

364. Prorock A J., Hafezi-Moghadam A., Laubach V.E. et al. Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase // Am. J. Physiol. Heart Ciric. Physiol. 2003. - Vol. 284. - N 1. - P. H133-H140.

365. Pryor W.A., Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite // Ann N Y Acad. Sei. -1993. Vol. 686. -P. 12-27.

366. Pueyo M.E., Michel J.B. Angiotensin II receptors in endothelial cells // Gen. Pharmacol. -1997. Vool. 29. - P. 691-696.

367. Quehenberger P., Bierhaus A., Fasching P. et al. Endothelin 1 transcription is controlled by nuclear fac-tor-kappaB in AGE-stimulated cultured endothelial cells // Diabetes. 2000. - Vol. 49. - P. 1561-1570.

368. Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease//Am. J. Med. 1998.-Vol. 105.-N 1A.-P. 325395.

369. Radi R., Beckman J.S., Bush K.M., Freeman B.A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide // J. Biol. Chem. -1991. Vol. 266. - P. 4244-4250.

370. Raitakari O.T., Adams M.R., McCredie R.J. et al. Oral vitamin C and endothelial function in smokers: short term improvement, but no sustained beneficial effect//J. Am. Coll. Cardiol. 2000. - Vol. 35.-P. 1616-1621.

371. Raitakari O.T., Adams M.R., McCredie RJ. et al. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults // Ann Intern. Med. -1999. Vol. 130. - P. 578-581.

372. Ramos C.L., Huo Y., Jung U. et al. Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice // Circ. Res. -1999. Vol. 84. - P. 1237-1244.

373. Randall M.D., Alexander S.Ph, Bennett T. An endogenous cannabinoid as an endothelium-derived vasorelaxant // Biochem. Biophys. Res. Commun. 1996. - Vol. 229. P. 114-120.

374. Randi A.M., Biguzzi E., Falciani F. et al. Identification of differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina by cDNA array analysis // Thromb. Haemost. 2003. - N 1. - P. 829835.

375. Rassaf T., Kletnbongard P., Preik M. et al. the systemic vasodilator effects of intravenously applied NO: experimental and clinical Study on the fate of NO in human blood // Circ. Res. 2002. - Vol. 91. - P. 470-477.

376. Rattan V., Sultana C., Shen Y. et al. Oxidant stress-induced transendothelial migration of monocytes is linked to phosphoiylation of PECAM-1 // Am. Physiol. -1997. Vol 273. P. E453-E461.

377. Reininger A. J., Heijnen H.F., Schumann H. et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress //Blood.-2006.-Vol. 107.-P. 3537-3545.

378. Rickles F.R., Hoyer L.W., Rick M.E., Ahr D.J. The effects of epinephrine infusion in patients with von Willebrand's disease // J. Clin. Invest. 1976. - Vol. 57. -P. 1618-1625.

379. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention I I Circulation. 2003. -107. - P. 363-369.

380. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women // Circulation. 2003. - Vol. 107. - N 3. - P. 391— 397.

381. Risau W., Flamme I. Vasculogenesis // Ann Rev. Cell. Dev. Biol. 1995. -Vol. 11.-P. 73-91.

382. Ritthaler U., Dedg Y., Zhang Y. et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease // Am. J. Pathol. 1995. -Vol. 146. -N3.-P 688-694.

383. Rosa Bernal-Lopez M., Ainhoa Ripodas, Paloma Aragoncillo et al. Atheromatous plaque from human carotid artery: Potential involvement of the endothelin-1 and their receptors // Proc. Biochem. 2009.-Vol. 44.-N ll.-P. 12311236.

384. Ross R. Atherosclerosis: an inflammatory disease //N. Engl. J. Med. -1999. -Vol. 340.-P. 115-126.

385. Rowland L.P., Shneider N. A. Amyotrophic lateral sclerosis // N. Engl. J. Med. -2001.-Vol. 344.-P. 1688-1700.

386. Russell F.D., Davenport A.P. Secretory pathways in endothelin synthesis // Br. J. Pharmacol. -1999. Vol. 126. -P. 391-398.

387. Saito Y., Nakao K., Mukoyama M. et al. Increased plasma endothelin levels in patients with essential hypertension // N. Engl. J. Med. 1990. - Vol. 322. - P. 205

388. Sakai H., Goto S., Kim J.Y. et al. Plasma concentration of von Willebrand factor in acute myocardial infarction // Thromb. Haemost. 2000. - Vol. 84. - P. 204209.

389. Sakata N., Imanaga Y., Meng J. et al. Immunohistochemi-cal localization of different epitopes of advanced glycation end products in human atherosclerotic lesions //Atherosclerosis. 1998. - Vol. 141. - P. 61-75.

390. Savage B., Saldivar E., Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor // Cell. -1996. Vol. 84. -P. 289-297.

391. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease // Circulation.-2000.-Vol. 101.-P. 1899-1906.

392. Schiffrin E.L., Thibault G. Plasma endothelin in human essential hypertension // Am. Hypertens. 1991. - N 4. - P. 303-308.

393. Schiffrin E.L., Touyz RM. Vascular biology of endothelin // J. Cardiovasc. Pharmacol.- 1998.-Vol. 32.-Suppl. 3.-P. S2-13.

394. Schleef R.R., Loskutoff D.J. Fibrinolytic system of vascular endothelial cells. Role ofplasminogen activator inhibitors // Haemostasis. -1988. Vol. 18. -P. 328341.

395. Schleimer R.P., Sterbinsky S.A., Kaiser J. et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression ofVCAM-1// Immunol. -1992. -Vol. 148.-P. 1086-1092.

396. Schneiderman J., Sawdey M.S., Keeton M.R. et al. Increased tupe 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries // Proc. Natl. Acad. Sci. USA. 1992. - Vol. 89. - N 15. - P. 6998-7002.

397. Scholz D., Devaux B., Hirche A. et al. Expression of adhesion molecules is specific and time-dependent in cytokine-stimulated endothelial cells in culture // Cell. Tissue. Res. 1996. - Vol. 284. - P. 415-423.

398. Schorer A.E., Moldow C.F., Rick M.E. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells // Br. J. Haematol. -1987.-Vol. 67. P. 193-197.

399. Schwartz R.S., Holmes D.R. Jr., Topol E.J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms // J. Am. Coll. Cardiol. -1992. Vol. 20.-P. 1284-1293.

400. Sell D., Monnier V.M. Structure elucidation of senescence cross-link from human extracellular matrix: implication of pentoses in the aging process // Biol. Chem. 1989. - Vol. 264. - P. 21597-21602.

401. Seyrantepe V., Hinek A., Peng J. et al. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1 //Circulation.-2008.-Vol. 117.-P. 1973-1981.

402. Shamsuzzaman A.S., Winnicki M., Lanfranchi P. et al. Elevated C-reactive protein in patients with obstructive sleep apnea // Circulation. 2002. - Vol. 105. - P. 2462-2464.

403. Shi G.Y., Hau J.S., Wang S J. et al. Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells // J. Biol. Chem. -1992. -Vol. 267. P. 19363-19368.

404. Shichiri M., Hirata Y., Ando K. et al. Plasma endothelin levels in hypertension and chronic renal failure // Hypertension. -1990. Vol. 15. - P. 493-496.

405. Siedlecki C.A., Lestini B.J., Kottke-Marchant K.K. et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor // Blood. -1996. Vol. 88. - P. 2939-2950.

406. Sies H. Oxidative stress: oxidants and antioxidants // Exp. Physio. -1997. -Vol. 82.-P. 291-295.

407. Sigwart U., Puel J., Mirkovitch V. et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty//N. Engl. J. Med.-1987.-Vol. 316.-N 12.-P. 701-706.

408. Singh U., Devaraj S., Jialal I. C-Reactive Protein Stimulates Myeloperoxidase Release from Polymorphonuclear Cells and Monocytes: Implications for Acute Coronary Syndromes // Clin. Chem. 2009. - Vol. 55. -N 2. - P. 361-364.

409. Sjogren L.S., Gan L., Doroudi R. et al. Fluid shear stress increases the intracellular storage pool of tissue-type plasminogen activator in intact human conduit vessels // Thromb. Haemost. 2000. - Vol. 84. - P. 291-298.

410. Smith D.T., Hoetzer G.L., Greiner J.J. et al. Endothelial release of tissue-type plasminogen activator in the human forearm: role of nitric oxide // J. Cardiovasc. Pharmacol. 2003. - Vol. 42. - P. 311-314.

411. Snell P.G., Mitchell J.H. Physical inactivity. An easily modified risk factor? // Circulation.-1999.-Vol. 100.-P. 2-4.

412. Solheim S., Arnesen H., PhD, Eikvar L. et al. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction // Am. J. Cardiol. -2003. Vol. 92. -N 7. - P. 843-845.

413. Sorensen K.E., Celermajer D.S., Spiegelhalter DJ. et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility //Br. Heart. J. -1995. Vol. 74. - P. 247-253.

414. Sorensen K.E., Kristensen I.B., Celermajer D.S. Atherosclerosis in the human brachial arteiy // J. Am. Coll. Cardiol. -1997. 29. - P. 318-322.

415. Spatz M., Kawai N., Merkel N. et al. Functional properties of cultured endothelial cells derived from large microvessels of human brain // Am. J. Physiol. — 1997. Vol. 272. - N 1. - PL 1. - C231-C239.

416. Sprengers E.D., Princen H.M., Kooistra T., Hinsbergh V.W. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2//J. Lab. Clin. Med.-1985.-Vol. 105.-P. 751-758.

417. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm // Cell. -1994. Vol. 76. -P. 301-314.

418. Stade B.G., Messer G., Riethmuller G. et al. Structural characteristics of the 5' region of the human ICAM-1 gene // Immunobiology. -1990. Vol. 182. - P. 79-87.

419. Stamler J.S., Singel DJ., Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms // Science. -1992. Vol. 258. - P. 1898-1902.

420. Steegmaier M., Borges E., Berger J. et al. The E-selectin-ligand ESL-1 is located in the golgi as well as on microvilli on the cell surface // Cell. Sei. -1997. -Vol. 110.-P. 687-694.

421. Stein C.M., Brown N., Vaughan D.E. et al. Regulation of local tissue-type plasminogen activator release by endotheliumdependent and endothelium-independent agonists in human vasculature // J. Am. Coll. Cardiol. -1998. Vol. 32. - P. 117-122.

422. Stoll M., Meffert S., Stroth U. et al. Growth or anti-growth: angiotensin and the endothelium // Hypertens. -1995. Vol. 13. - P. 1529-1534.

423. Subramaniam M., Koedam J.A., Wagner D.D. Divergent fates of P- and E-selectins after their expression on the plasma membrane // Mol. Biol. Cell. -1993. N 4.-P. 791-801.

424. Sumeray M.S., Rees D.D., Yellon D.M. Infarct size and nitric oxide synthase in murine myocardium // J. Mol. Cell. Cardiol. 2000. - Vol. 32. - P. 35-42.t 191

425. Taddei S., Virdis A., Ghiadoni L. et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications // Drugs. 2002. - Vol. 62. - P. 265284.

426. Taddei S., Virdis A., Ghiadoni L. et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension // Circulation. -1998. Vol. 97. - P. 2222-2229.

427. Taddei S., Virdis A., Mattei P. et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension // Hypertension. -1993. Vol. 21. - P. 929-933.

428. Takeuchi M., Nagura H., Kaneda T. DDAVP and epinephrine-induced changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa // Blood. -1988. Vol. 72. - P. 850-854.

429. Tamirisa P., Frishman W.H., Kumar A. Endothelin and endothelin antagonists. Roles in cardiovascular health and disease // Am. Heart. J. -1995. Vol: 130. - P. 601-610.

430. Tanabe T., Maeda S., Miyauchi T. et al. Exercise training improves ageing-induced decrease in eNOS expression of the aorta // Acta Physiol. Scand. 2003. -Vol. 178.-P. 3-10.

431. Tatsuya Komaru, Shogen Isoyama, Nobuyo Sekiguchi et al. Coronary angioplasty ameliorates hypoperfusion-induced endothelial dysfunction in patients with stable angina pectoris // J. Am. Coil. Cardiol. -1996. Vol. 27. - P. 30-37.

432. Thanyasiri P., Celermajer D.S., Adams M.R. Endothelial dysfunction occurs in peripheral circulation in patients with acute and stable coronary artery disease // Am. J. Physiol. Heart. Circ. Physiol. -2005. Vol. 289. - N 2. - P. H513-H517.

433. Thompson D., Pepys M.B., Wood .SP. The physiological structure of human C-reactive protein and its complex with phosphocholine // Structure. 1999. -N 7. - P. 169-177.

434. Thygesen K., Alpert J.S., White H.D., Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction // Eur. Heart. J. 2007. - Vol. 28. - N 20. - P. 2525-2538.

435. Tiefenbacher C.P., Friedrich S., Bleeke T. et al. ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles // Am. J. Physiol. Heart Circ. Physiol. 2004. - Vol. 286. - N 4. - P. H1425-H1432.

436. Ting H.H., Timimi F.K., Haley E.A. et al. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia// Circulation. -1997. Vol. 95. - P. 2617-2622.

437. Toivonen A.M., Kulmala P., Savola K. et al. Soluble adhesion molecules in preclinical Type 1 diabetes: a prospective study // Diabetologia. 2004. - Vol. 46. - N 4. -P. 492-495.

438. Toutouzasa K., Colombob A., Stefanadisa C. Inflammation and restenosis after percutaneous coronary interventions // Eur. Heart J. 2004.—Vol. 25. - N19. - P. 1679-1687.

439. Tran Due A.T., Schwab A. J., Simard A. et al. Reduction in hepatic endothelin-1 clearance in cirrhosis // Clin. Sci. 2003. - Vol. 105. - P. 227-234.

440. Treasure C.B., Manoukian S.V., Klein J.L. et al. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients // Circ. Res. 1992. -Vol. 71. -P. 776-781.

441. Trepakova E.S., Cohen R.A., Bolotina V.M. Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-dependent refilling ol Ca2+ stores // Circ Res. 1999. - Vol. 84. - P. 201-209.

442. Triggle C.R., Ding H. Endothelium-derived hyperpolarizing factor: is there a novel chemical mediator? // Clin. Exp. Pharmacol. Physiol. 2002. - Vol. 29. - P. 153-160.

443. Turitto V.T., Weiss H.J, Zimmerman T.S., Sussman I.I. Factor VHI/von Willebrand factor in subendothelium mediates platelet adhesion // Blood. -1985. — Vol. 65.-P. 823-831.

444. Ueno H., Kanellakis P., Agrotis A. et al. Blood How regulates the development of vascular hypertrophy, smooth muscle cell proliferation, and endothelial cell nitric oxide synthase in hypertension // Hypertension. 2000. - Vol. 36. - P. 89-96.

445. Ugustin H.G., Kozian D.H., Johnson R.C. Differentiation of endothelial cells: analysis of constitutive and activated cells fenotypes //. Byoessays. -1994. Vol. 16. -P. 901-906.

446. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease // Am. J. Cardiol. 2002. - Vol. 89. - N 2A. - P. 3 A-9A.

447. Urakami-Harasawa L., Shimokawa H., Nakashima M. et al. Importance of endothelium-derived hyperpolarizing factor in human arteries // Clin. Invest. -1997. -Vol. 100.-P. 2793-2799.

448. Ushio-Fukai M., Tang Y., Fukai T. Novel role of gp91 (phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis//Circ. Res. -2002. Vol. 91. -N 1. -P. 160-167.

449. Valen G., Yan Z.Q., Hansson G.K. Nuclear factor kappa-B and the heart // J. Am. Coll. Cardiol. 2001. - Vol. 38.-P. 307-314.

450. Valgimigli M., Merli E., Malagutti P. et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress // Arch. Biochem. Biophys. 2003. - Vol. 420. -N 2. - P. 255-261.

451. Venugopal S.K., Devaraj S., Yuhanna I. et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells // Circulation.-2002.-Vol. 106.-P. 1439-1441.

452. Verma S., Li S.H., Badiwala M.V. et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein // Circulation. -2002.-Vol. 105.-P. 1890-1896.

453. Verma S., Wang C.H., Li S.H. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis // Circulation. -2002.-Vol. 106.-P. 913-919.

454. Vischer U.M. von Willebrand factor, endothelial dysfunction, and cardiovascular disease // J. Thromb. Haemost. 2006. - |N 4. - P. 1186-1193.

455. Visioli F. Effects of vitamin E on the endothelium: equivocal? Alpha-tocopherol and endothelial dysfunction // Cardiovasc. Res. — 2001. Vol. 51.- N 2. -P. 198-201.

456. Vita J.A., Keaney J.F. Hormone replacement therapy and endothelial function: the exception that proves the rule? // Arterioscler. Thromb. Vase. Biol. 2001. - Vol. 21.-P. 1867-1869.

457. Vita J.A., Treasure C.B., Nabel E.G. Coronary vasomotor response to acetylcholine relate to risk factor for coronary artery disease // Circulation. -1990. -Vol. 81.-P. 491-498.

458. Vogel RA. Cholesterol lowering and endothelial function // Am. J. Med. -1999.-Vol. 107.-P. 479-487.

459. Wagner D.D. Cell biology of von Willebrand factor // Annu Rev. Cell. Biol. -1990.-N 6.-P. 217-246.

460. Walford G., Loscalzo J. Nitric oxide in vascular biology // J. Thromb. Haemost. -2003.-N l.-P. 2112-2118.

461. Wall U., Jern C., Jem S. High capacity for tissue-type plasminogen activator release from vascular endothelium in vivo // J. Hypertens. -1997. Vol. 15. -P. 1641-1647.

462. Wang C.H., Li S.H., Weisel R.D. et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle // Circulation. 2003. - Vol. 107.-P. 1783-1790.

463. Wang X., Quinn P.J. Vitamin E and its function in membranes // Prog. Lipid. Res. 1999. - Vol. 38. - P. 309-336.

464. Watkins M.T., Patton G.M., Soler H.M. et al. Synthesis of 8-epi-prostaglandin £2alpha by human endothelial cells: role of prostaglandin Ь2 synthase // Biochem. J. — 1999. Vol. 344. - P. 747-754.

465. Welt F.G., Tso C., Edelman E.R. et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury // Vase. Med. 2003. -N 8. -P. 1-7.

466. Wild M.K., Huang M.C., Schulze-Horsel U. et al. Affinity, kinetics, and thermodynamics of E-selectin binding to E-selectin ligand-1 // Biol. Chem. 2001. — Vol. 276.-P. 31602-31612.

467. Williams I.L., Chowienczyk P.J., Wheatcroft S.B. et al. Endothelial Function and Weight Loss in Obese Humans // Obes. Surg. 2005. - Vol. 15. -N 7. - P. 10551060.

468. Williams S.B., Goldfine A.B., Timimi F.K. et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo // Circulation. -1998.-Vol. 97.-P. 1695-1701.

469. Williams S.B., Upchurch GRJ et al. Homocysteine decreases bioaviable nitric oxide by a mechanism involving glutathione peroxidase // J. Biol. Chem.—1997.— Vol. 272-P. 17012-17017.

470. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis//J. Clin. Invest. -1991. Vol. 88. -P. 1785-1792.

471. Wolin M.S. Interactions of oxidants with vascular signaling systems // Artenoscler. Thromb. Vase. Biol. 2000. - Vol. - 20. - P. 1430-1442.

472. Woo K.S., Chook P. et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in human // Circulation.—1997—Vol. 96 — P. 2542-2544.

473. Wood K.M., Cadogan M.D., Ramshaw A.L. et al. The distribution of adhesion molecules in human atherosclerosis // Histopathology. 1993. - Vol. 22. - P. 437-444.

474. Xu D., Emoto N., Giaid A. et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 // Cell. -1994. Vol. 78. -P. 473-485.

475. Yamashita A., Sumi T., Goto S. et al. Detection of von Willebrandfactor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction // Am. J. Cardiol. 2006. - Vol. 97. - P. 26-28.

476. Yao L., Pan J., Setiadi H. et al. Interleukin 4 or oncostatin m induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells // Exp. Med.-1996.-Vol. 184.-P. 81-92.

477. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques // Am. J. Pathol. -2001.-Vol.-158.-P. 1039-1051.

478. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease // Brain. Res. -2000.-Vol. 887.-P. 80-89.

479. Yeboah J., Crouse J.R., Fang-Chi Hsu et al. Brachial Flow-Mediated Dilation Predicts Incident Cardiovascular Events in Older Adults The Cardiovascular Health Study//Circulation.-2007.-Vol. 115.-P. 2390-2397.

480. Yip H.K., Wu C.J., Chang H.W. et al. Prognostic Value of Circulating Levels of Endothelin-1 in Patients After Acute Myocardial Infarction Undergoing Primary Coronaiy Angioplasty//Chest.-2005.-Vol. 127.-N5.-P. 1491-1497.

481. Yoshida M., Imaizumi T., Ando S. et al. Impaired forearm vasodilation by acetylcholine in patients with hypertension // Heart. Vessels. 1991. - N 6. - P. 218223.

482. Yoshizumi M., Perrella M.A., Burnett J.C. Jr. et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life // Circ. Res. -1993. Vol. 73. -P. 205-209.

483. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? // Atherosclerosis. -2000. Vol. 148. -P. 209-214.

484. Yusuf S., Dagenais G., Pogue J. et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investimators //N. Engl. J. Med. -2000. Vol. 342. -N 3. -P. 154-160.

485. Yusuf S., Seleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart

486. Outcomes Prevention Evaluation Study Investigators. // N. Engl. J. Med. 2000. -Vol. 342. -N3.-P. 145-153.

487. Zeiher A.M., Drexler H., Saurbier B. et al. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension // Clin. Invest. 1993. - Vol. 92. - P. 652662.

488. Zhang X. at al. Effects of homocysteine on endothelial nitric oxide production // Am. J. Physiol. Renal. Physiol.—2000.—Vol. 279.—P.671-678.

489. Ziegler T., Silacci P., Harrison V.J. et al. Nitric Oxide synthase expression in endothelial cells exposed to mechanical forces // J. Am. Heart. Associât. 1998. - Vol. 32.-P. 351-355.

490. Zou M.H., Shi C., Cohen R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite // J. Clin. Invest. -2002.-Vol. 109.-P. 817-826.

491. Zouridakisl E.G., Schwartzmanl R., Garcia-Moll X. et al. Kaskil Increased plasma endothelin levels in angina patients with rapid coronary arteiy disease progression // Eur. Heart. J. 2001. - Vol. 22,- P. 1578-1584.

492. Zouridakisl E.G., Vanhoutte P.M. The alternative: EDHF // Mol. Cell. Cardiol. -1999.-Vol. 31.-P. 15-22. ;7